RBC Capital Assumes Sarepta Therapeutics (SRPT) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Sarepta Therapeutics (SRPT) PT Raised to $77 at Leerink Partners; 'Ability to Dose Escalate Is Key'
January 19, 2018 8:49 AM ESTLeerink Partners raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $77.00 (from $72.00) while maintaining an Outperform rating.
Analyst Joseph Schwartz commented, "Given Sarepta's enhanced emphasis on R&D now, we have taken a closer look at the company's use of peptide-conjugated phosphorodiamidate... More
